185 ENGOT-en11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo + adjuvant chemotherapy ± radiotherapy for high-risk endometrial cancer

T Van Gorp; MR Mirza; A Lortholary; IB Vergote; D Cibula; A Walther; A Savarese; MP Barretina-Ginesta; FU Ortac; C Papadimitriou; L Bodnar; CH Lai; K Hasegawa; X Xie; EL Barber; R Coleman; J Lichfield; A Grandhi; B Slomovitz

doi:10.1136/ijgc-2021-ESGO.123

Article info

Endometrial cancer

185 ENGOT-en11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo + adjuvant chemotherapy ± radiotherapy for high-risk endometrial cancer

Free

Authors

T Van Gorp UZ Leuven, Leuven, Belgium PubMed articles Google scholar articles
MR Mirza NSGO-CTU and Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark PubMed articles Google scholar articles
A Lortholary Centre Catherine de Sienne, Hôpital Privé du Confluent, Nantes, France PubMed articles Google scholar articles
IB Vergote BGOG and University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium PubMed articles Google scholar articles
D Cibula Department of Obstetrics and Gynecology, General Faculty Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic PubMed articles Google scholar articles
A Walther Bristol Cancer Institute, University Hospitals Bristol, Bristol, UK PubMed articles Google scholar articles
A Savarese Istituto Nazionale Tumori Regina Elena, Rome, Italy PubMed articles Google scholar articles
MP Barretina-Ginesta Catalan Institute of Oncology and Girona Biomedical Research Institute, Medical School University of Girona, Girona, Spain PubMed articles Google scholar articles
FU Ortac Ankara University School of Medicine, Ankara, Turkey PubMed articles Google scholar articles
C Papadimitriou Aretaieio University Hospital, National and Kapodistrian University of Athens, Athens, Greece PubMed articles Google scholar articles
L Bodnar Department of Oncology and Immunooncology, Warmian-Masurian Cancer Center of the Ministry of the Interior and Administration’s Hospital, Olsztyn, Poland PubMed articles Google scholar articles
CH Lai TGOG and Department of Gynecology and Obstetrics, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan PubMed articles Google scholar articles
K Hasegawa Department of Gynecologic Oncology, Saitama Medical University, Hidaka, Saitama Prefecture, Japan PubMed articles Google scholar articles
X Xie Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, China PubMed articles Google scholar articles
EL Barber Northwestern University Feinberg School of Medicine, Chicago, IL, USA PubMed articles Google scholar articles
R Coleman US Oncology Research, The Woodlands, TX, USA PubMed articles Google scholar articles
J Lichfield MSD, UK PubMed articles Google scholar articles
A Grandhi Merck and Co., Inc., Kenilworth, NJ, USA PubMed articles Google scholar articles
B Slomovitz Broward Health, Fort Lauderdale, FL, USA PubMed articles Google scholar articles

Citation

Van Gorp T, Mirza M, Lortholary A, et al

185 ENGOT-en11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo + adjuvant chemotherapy ± radiotherapy for high-risk endometrial cancer

International Journal of Gynecologic Cancer 2021;31:A79-A80.

Publication history

First published October 12, 2021.

Online issue publication

January 10, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password